Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
Holding CGON?
Track your performance easily
CGON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.77 - $50.23
Previous Close$32.24
Volume588.67K
Average Volume (3M)660.66K
Market Cap
$2.22B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 12, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding67,629,675
10 Day Avg. Volume502,251
30 Day Avg. Volume660,663
Standard Deviation0.11
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)4.06
Price to Sales (P/S)3243.06
Price to Cash Flow (P/CF)-34.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$65.50Price Target Upside102.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
CG Oncology, Inc. News
PremiumCompany Announcements
CG Oncology’s Financial Results and Clinical Developments
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCretostimogene's safety profile shows zero Grade 3+ treatment-related adverse events and zero discontinuation rate, which is more favorable compared to TAR-200.
Financial StrengthCG Oncology finished with $540.7 million in cash, which should fund them through 2027 and possibly to cash flow positivity.
Market OpportunityThe potential of cretostimogene in muscle-invasive bladder cancer is highlighted as a significant, underappreciated segment with over $1 billion market potential.
Bears Say
Clinical StudyThe SunRISe-2 study was discontinued due to TAR-200 failing to show superiority to the chemoradiation comparator arm.
Data InterpretationConfusion on the interpretation of the K-M estimates is likely to persist until final results are seen.
Market CompetitionThe commercial bar is high for CG Oncology given the competition is BCG, indicating challenges in gaining market share.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $25.77 and its highest was $50.23 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
Currently, no data Available
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Nov 12, 2024 which is 10 days ago.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Aug 08, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.356 by $0.076.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -$0.35.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 67,629,680 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.356. Following the earnings report the stock price went down -6.828%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Among the largest hedge funds holding CG Oncology, Inc.’s share is RA Capital Management. It holds CG Oncology, Inc.’s shares valued at 53M.
---
CG Oncology, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.50 (102.54% Upside)
$65.50 (102.54% Upside)
Blogger Sentiment
Neutral
CGON Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 590.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
Company Description
CG Oncology, Inc.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.
---
CGON Stock 12 Month Forecast
Average Price Target
$65.50
▲(102.54% Upside)
Technical Analysis
Best Analysts Covering CGON
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-11.67%
assigned a buy rating 10 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -11.67% per trade.
---